1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Will there be a split off?

Discussion in 'Allergan' started by anonymous, Jun 19, 2019 at 2:40 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Thoughts?

    Will it be 1 company to be botox/Eye care and another to be gen med?
     

  2. anonymous

    anonymous Guest

    Yes, there will be a split. Anyone that didn’t see this coming has their head in the sand.

    PCR reps maybe GI COULD be losers in this.
     
  3. anonymous

    anonymous Guest

    Perhaps David Pyott will lead one of the 2 companies?
     
  4. anonymous

    anonymous Guest

    no.
     
  5. anonymous

    anonymous Guest

    Why GI and PCR have the only product line worth anything?

    IS and WH will be sent packing once again.
     
  6. anonymous

    anonymous Guest

    GI franchise will be spun off and combined with Ironwood to form a new entity.
     
  7. anonymous

    anonymous Guest


    GI and PCR have the only product line worth anything? No, sorry. Botox and Eye care reps have the only products worth anything.

    PCR reps are redundant. They have products that the specialty reps ALREADY have.
     
  8. anonymous

    anonymous Guest

    I was talking about GM. The Botox and Eye care side is golden.
     
  9. anonymous

    anonymous Guest

    How can you ever split Botox between specialty and genmed?
     
  10. anonymous

    anonymous Guest